14
views
0
recommends
+1 Recommend
3 collections
    0
    shares
      Are you tired of sifting through news that doesn't interest you?
      Personalize your Karger newsletter today and get only the news that matters to you!

      Sign up

      • Record: found
      • Abstract: found
      • Article: found

      Ocular Pathology Recommendations during COVID-19 from the American Association of Ophthalmic Oncologists and Pathologists (AAOOP)

      letter

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Dear Editor, With the COVID-19 outbreak, ocular pathologists must be particularly aware of exposure to the virus in their practice. Any specimen could be a source of infection [1, 2]. General pathologists have described cases in which patients who were asymptomatic and had lung resections for tumor subsequently tested positive for COVID-19. No transmission to pathologists has been documented as of the time of submission of these recommendations, but it is essential that we protect ourselves from the possibility of exposure. The highest risk of exposure exists during frozen section, when handling fresh, unfixed tissue. In the general pathology scenario, lung/respiratory, nasal, and oral mucosa specimens are the most critical specimens to be protected against. All personnel (trainees, staff, pathology assistants, and histotechnologists) in frozen section areas should wear personal protective equipment, at least surgical masks and eye protective glasses, but preferably N95 masks when handling these specimens. Wearing at least a surgical mask when handling fresh lung tissue has always been recommended, long before COVID-19. Frozen sections for ocular pathology specimens of highest risk would be conjunctiva, nasolacrimal system, nasal, and sinus specimens − but any other fresh ocular tissue is potentially infectious. When a frozen section is needed (a situation in which the surgical plan would change depending on the intraoperative diagnosis) and indicated for conjunctiva, nasolacrimal system, nasal, and sinus specimens, the same precautions should be taken as for respiratory specimens: All trainees, staff, pathology assistants, and histotechnologists in frozen section areas should don personal protective equipment, at least surgical masks, but preferably N95 masks when handling these specimens. It is also recommended that ocular pathologists adhere to their own frozen section's laboratory guidelines for the era of COVID-19 for any specimens they process. It is recommended that all handling of fresh tissues occur in the operating room at the time of submitting the specimens for testing, as detailed in the following scenarios. In ocular specimens where there is a need to exclude infectious process: the specimen should be divided in the operating room into the specimen for Microbiology and the specimen for Surgical Pathology. Submit the fresh specimen to microbiology directly (not to frozen sections or pathology) and place the other specimen immediately in formalin for pathology. In ocular specimens where there is a need to perform flow cytometry or molecular testing: the specimen should be divided in the operating room into the specimen for Flow Cytometry/Molecular and the specimen for Surgical Pathology. Submit the fresh specimen to Flow Cytometry (in RPMI or in a wet TELFA paper with a balanced salt solution) or Molecular (in a sterile container, dry) directly to the appropriate laboratory (not to frozen sections for the pathologist to divide) and place the other specimen immediately in formalin for Surgical Pathology. Always follow the guidelines of your own pathology department, but these are specific common scenarios in which specimens in eye pathology should be considered for special handling. For up-to-date guidelines on CDC recommendations for laboratory COVID-19 biosafety please refer to the following website link: https://www.cdc.gov/coronavirus/2019-ncov/lab/lab-biosafety-guidelines.html Disclosure Statement The authors have no conflicts of interest to declare. Funding Sources No funding source for this work. Author Contributions All authors contributed equally to final statements and form of the manuscript.

          Related collections

          Author and article information

          Journal
          Ocul Oncol Pathol
          Ocul Oncol Pathol
          OOP
          Ocular Oncology and Pathology
          S. Karger AG (Allschwilerstrasse 10, P.O. Box · Postfach · Case postale, CH–4009, Basel, Switzerland · Schweiz · Suisse, Phone: +41 61 306 11 11, Fax: +41 61 306 12 34, karger@karger.com )
          2296-4681
          2296-4657
          21 April 2020
          : 6
          : 3
          : 1-2
          Affiliations
          [1] aHouston Methodist Hospital, Houston, Texas, USA
          [2] bWills Eye Hospital and Jefferson University Hospital, Philadelphia, Pennsylvania, USA
          [3] cEmory Eye Center, Atlanta, Georgia, USA
          [4] dMichigan State University College of Human Medicine, Grand Rapids, Michigan, USA
          [5] eMayo Clinic, Rochester, Minnesota, USA
          [6] fUniversity of Texas MD Anderson Cancer Center, Houston, Texas, USA
          Author notes
          *Patricia Chévez-Barrios, MD, Chair in Ocular Pathology, Department of Pathology and Genomic Medicine, Houston Methodist Hospital, 6565 Fannin St, M227, Houston, TX 77030 (USA), pchevez-barrios@ 123456houstonmethodist.org
          Article
          oop-0001
          10.1159/000507735
          7206350
          5b9cb0e0-2a40-4ae7-88d4-1e2b748965f0
          Copyright © 2020 by S. Karger AG, Basel

          This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

          History
          : 31 March 2020
          : 3 April 2020
          : 2020
          Page count
          References: 2, Pages: 2
          Categories
          Letter to the Editor

          Comments

          Comment on this article